609 related articles for article (PubMed ID: 25703085)
21. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
[TBL] [Abstract][Full Text] [Related]
22. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study.
Yakaryilmaz F; Guliter S; Savas B; Erdem O; Ersoy R; Erden E; Akyol G; Bozkaya H; Ozenirler S
Intern Med J; 2007 Apr; 37(4):229-35. PubMed ID: 17388862
[TBL] [Abstract][Full Text] [Related]
23. Changes in peroxisome proliferator-activated receptor alpha target gene expression in peripheral blood mononuclear cells associated with non-alcoholic fatty liver disease.
Li TT; Tan TB; Hou HQ; Zhao XY
Lipids Health Dis; 2018 Nov; 17(1):256. PubMed ID: 30428868
[TBL] [Abstract][Full Text] [Related]
24. Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study.
Chan WK; Ida NH; Cheah PL; Goh KL
J Dig Dis; 2014 Oct; 15(10):545-52. PubMed ID: 25060399
[TBL] [Abstract][Full Text] [Related]
25. Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features.
Vonghia L; Magrone T; Verrijken A; Michielsen P; Van Gaal L; Jirillo E; Francque S
PLoS One; 2015; 10(11):e0143380. PubMed ID: 26599575
[TBL] [Abstract][Full Text] [Related]
26. Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease.
Sharma H; Estep M; Birerdinc A; Afendy A; Moazzez A; Elariny H; Goodman Z; Chandhoke V; Baranova A; Younossi ZM
J Gastroenterol Hepatol; 2013 Aug; 28(8):1410-5. PubMed ID: 23663110
[TBL] [Abstract][Full Text] [Related]
27. Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
Enooku K; Tsutsumi T; Kondo M; Fujiwara N; Sasako T; Shibahara J; Kado A; Okushin K; Fujinaga H; Nakagomi R; Minami T; Sato M; Uchino K; Nakagawa H; Kondo Y; Asaoka Y; Tateishi R; Ueki K; Ikeda H; Yoshida H; Moriya K; Yotsuyanagi H; Kadowaki T; Koike K
J Gastroenterol; 2020 Feb; 55(2):227-243. PubMed ID: 31602526
[TBL] [Abstract][Full Text] [Related]
28. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis.
Younossi ZM; Gorreta F; Ong JP; Schlauch K; Del Giacco L; Elariny H; Van Meter A; Younoszai A; Goodman Z; Baranova A; Christensen A; Grant G; Chandhoke V
Liver Int; 2005 Aug; 25(4):760-71. PubMed ID: 15998427
[TBL] [Abstract][Full Text] [Related]
29. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats.
Zhao X; Xue J; Wang XL; Zhang Y; Deng M; Xie ML
Int Immunopharmacol; 2014 Sep; 22(1):176-81. PubMed ID: 24993341
[TBL] [Abstract][Full Text] [Related]
30. The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.
El-Karaksy HM; El-Raziky MS; Fouad HM; Anwar GM; El-Mougy FM; El-Koofy NM; El-Hennawy AM
Diabetes Metab Syndr; 2015; 9(2):114-9. PubMed ID: 25470627
[TBL] [Abstract][Full Text] [Related]
31. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
[TBL] [Abstract][Full Text] [Related]
32. Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis.
Bril F; Maximos M; Portillo-Sanchez P; Biernacki D; Lomonaco R; Subbarayan S; Correa M; Lo M; Suman A; Cusi K
J Hepatol; 2015 Feb; 62(2):405-11. PubMed ID: 25195551
[TBL] [Abstract][Full Text] [Related]
33. Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity.
Régnier M; Polizzi A; Smati S; Lukowicz C; Fougerat A; Lippi Y; Fouché E; Lasserre F; Naylies C; Bétoulières C; Barquissau V; Mouisel E; Bertrand-Michel J; Batut A; Saati TA; Canlet C; Tremblay-Franco M; Ellero-Simatos S; Langin D; Postic C; Wahli W; Loiseau N; Guillou H; Montagner A
Sci Rep; 2020 Apr; 10(1):6489. PubMed ID: 32300166
[TBL] [Abstract][Full Text] [Related]
34. Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα.
Liang N; Damdimopoulos A; Goñi S; Huang Z; Vedin LL; Jakobsson T; Giudici M; Ahmed O; Pedrelli M; Barilla S; Alzaid F; Mendoza A; Schröder T; Kuiper R; Parini P; Hollenberg A; Lefebvre P; Francque S; Van Gaal L; Staels B; Venteclef N; Treuter E; Fan R
Nat Commun; 2019 Apr; 10(1):1684. PubMed ID: 30975991
[TBL] [Abstract][Full Text] [Related]
35. The role and regulation of the peroxisome proliferator activated receptor alpha in human liver.
Kersten S; Stienstra R
Biochimie; 2017 May; 136():75-84. PubMed ID: 28077274
[TBL] [Abstract][Full Text] [Related]
36. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology.
Jung KY; Cho SY; Kim HJ; Kim SB; Song IH
J Clin Gastroenterol; 2014; 48(10):883-8. PubMed ID: 24440936
[TBL] [Abstract][Full Text] [Related]
37. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
Lemoine M; Ratziu V; Kim M; Maachi M; Wendum D; Paye F; Bastard JP; Poupon R; Housset C; Capeau J; Serfaty L
Liver Int; 2009 Oct; 29(9):1431-8. PubMed ID: 19422483
[TBL] [Abstract][Full Text] [Related]
38. Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study.
Dongiovanni P; Rametta R; Fracanzani AL; Benedan L; Borroni V; Maggioni P; Maggioni M; Fargion S; Valenti L
BMC Gastroenterol; 2010 Sep; 10():102. PubMed ID: 20825652
[TBL] [Abstract][Full Text] [Related]
39. PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH.
Gastaldelli A; Sabatini S; Carli F; Gaggini M; Bril F; Belfort-DeAguiar R; Positano V; Barb D; Kadiyala S; Harrison S; Cusi K
Liver Int; 2021 Nov; 41(11):2659-2670. PubMed ID: 34219361
[TBL] [Abstract][Full Text] [Related]
40. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
Bril F; Barb D; Lomonaco R; Lai J; Cusi K
J Hepatol; 2020 Mar; 72(3):401-410. PubMed ID: 31589891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
